Expanded Access to Telisotuzumab Vedotin
Launched by ABBVIE · Mar 31, 2021
Trial Information
Current as of May 13, 2025
Available
Keywords
ClinConnect Summary
No description provided
Gender
Eligibility criteria
- Inclusion Criteria:
- • - The participant must not be eligible for a telisotuzumab vedotin clinical trial.
About Abbvie
AbbVie is a global biopharmaceutical company dedicated to developing innovative therapies that address complex health challenges. Founded in 2013 as a spin-off from Abbott Laboratories, AbbVie focuses on key therapeutic areas, including immunology, oncology, neuroscience, and virology. The company is committed to advancing scientific research and delivering groundbreaking treatments that enhance patient outcomes and quality of life. With a robust pipeline and a strong emphasis on collaboration, AbbVie strives to transform the future of medicine through its commitment to clinical excellence and patient-centered approaches.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
West Perth, Western Australia, Australia
Yau Ma Tei, , Hong Kong
Petakh Tikva, , Israel
Sacramento, California, United States
Mountain Lakes, New Jersey, United States
Cologne, , Germany
Gauting, , Germany
Ramat Gan, Tel Aviv, Israel
Jerusalem, , Israel
Patients applied
Trial Officials
ABBVIE INC.
Study Director
AbbVie
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials